Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit in New York City on Thursday, February 27, 2025.

As part of the event, David Moatazedi, President and CEO of Evolus, will host a fireside chat on Thursday, February 27, 2025, from 9:30 AM – 10:00 AM ET. A live webcast of the fireside chat can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will remain available for 90 days following the event.

About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau® and Nuceiva®, are registered trademarks and Evolysse is a trademark of Evolus, Inc.

Contacts

Investors:

Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications

Phone: (248) 202-9267

Email: ir@evolus.com

Media:

Email: media@evolus.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  224.95
+4.26 (1.93%)
AAPL  276.24
+4.75 (1.75%)
AMD  215.27
+11.49 (5.64%)
BAC  52.05
+0.49 (0.95%)
GOOG  317.34
+17.69 (5.90%)
META  613.60
+19.35 (3.26%)
MSFT  474.30
+2.18 (0.46%)
NVDA  181.67
+2.79 (1.56%)
ORCL  200.04
+1.28 (0.64%)
TSLA  419.16
+28.07 (7.18%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.